Patents
Sitemap › C07 - Organic chemistry › C07D - Heterocyclic compounds › C07D 401 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
Patents for C07D 401 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom (107,979)
11/2008
11/20/2008CA2686546A1 Novel peptide inhibitors of hepatitis c virus replication
11/20/2008CA2686385A1 Dihydroquinone and dihydronaphthridine inhibitors of jnk
11/20/2008CA2686091A1 New compounds
11/20/2008CA2685888A1 Substituted heterocyclic derivatives and their pharmaceutical use and compositions
11/20/2008CA2685761A1 New solid forms of fxa inhibitors
11/20/2008CA2684931A1 Oxime ester photoinitiators
11/20/2008CA2684666A1 Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
11/20/2008CA2684563A1 2-[4-(pyrazol-4-ylalkyl)piperazin-1-yl]-3-phenyl pyrazines and pyridines and 3-[4-(pyrazol-4-ylalkyl)piperazin-1-yl]-2-phenyl pyridines as 5-ht7 receptor antagonists
11/20/2008CA2683941A1 Nitrogen-containing six-membered aromatic ring derivatives and pharmaceutical products containing the same
11/20/2008CA2683195A1 Mono-hydrochloric salts of an inhibitor of histone deacetylase
11/20/2008CA2683074A1 Fungicide phenyl-pyrimidinyl-amino derivatives
11/20/2008CA2678335A1 Solid forms of a raf kinase inhibitor
11/20/2008CA2667447A1 Mapk/erk kinase inhibitors
11/19/2008EP1992624A1 Heteroarylamide pyrimidone compounds
11/19/2008EP1992621A1 Heteroarylamide-substituted pyrimidone derivatives for the treatment of neurodegenerative diseases
11/19/2008EP1992619A1 Process for preparing 2-(2-pyridylmethyl)-sulfinyl-1H-benzimidazoles and the intermediate compounds used therein
11/19/2008EP1992349A1 CGRP antagonists, their preparation and use as a medicament
11/19/2008EP1991540A1 Cinnoline derivatives as phosphodiesterase 10 inhibitors
11/19/2008EP1991539A1 New salts of an indole derivative and their use in medicine
11/19/2008EP1991532A2 Compositions and methods for inhibition of the jak pathway
11/19/2008EP1991531A1 Cinnoline and quinoxaline derivates as phosphodiesterase 10 inhibitors
11/19/2008EP1991530A1 Cinnoline derivatives as phosphodiesterase 10 inhibitors
11/19/2008EP1991528A2 Modulators of alpha7 nicotinic acetylcholine receptors and therapeutic uses thereof
11/19/2008EP1991233A2 Hydroxypiperidine derivatives and uses thereof
11/19/2008EP1751131B1 Mtp inhibiting aryl piperidines or piperazines substituted with 5-membered heterocycles
11/19/2008EP1532138B1 Inhibitors of tyrosine kinases
11/19/2008EP1427326B1 Combination therapy for the treatment of cancer
11/19/2008EP1307226B1 Vitronectin receptor antagonist pharmaceuticals
11/19/2008CN101309917A Inhibitors of the gastric h+, k+-atpase with enhanced therapeutic properties
11/19/2008CN101309916A Process for production of cinnamamide derivative
11/19/2008CN101309915A Compounds and compositions as lxr modulators
11/19/2008CN101309905A Substituted isoindolones and their use as metabotropic glutamate receptor potentiators
11/19/2008CN101307046A Tripeptidyl peptidase inhibitors
11/19/2008CN100434425C 4-quinazolone derivative and its use in anti-tumor medicine
11/19/2008CN100434420C Compound inhibiting dipeptidyl peptidase iv
11/18/2008US7453002 Five-membered heterocycles useful as serine protease inhibitors
11/18/2008US7452999 Chemical process for the preparation of intermediates to obtain N-formyl hydroxy-lamine compounds
11/18/2008US7452998 preparing an optically pure proton pump inhibitor having a sulfinyl structure using a chiral zirconium complex or a chiral hafnium complex; comprising oxidizing a corresponding sulfide
11/18/2008US7452997 Tetrahydro-indazole cannabinoid modulators
11/18/2008US7452995 Aryl aniline β2 adrenergic receptor agonists
11/18/2008US7452911 Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds
11/18/2008US7452909 such as 2-[4-(3-chloro-phenylethynyl)-2-methyl-imidazol-1-ylmethyl]-pyridine, used for treatment and/or prevention of nervous system disorders, as anxiolytic agents and as analgesics
11/18/2008US7452908 Amide derivatives
11/18/2008US7452906 For therapy of neurotraumatic diseases, cancer, chronic neurodegeneration, pain, migraine and cardiac hypertrophy
11/18/2008US7452903 ligands for Calcitonin gene related peptide; azepinone ligands; migranes; N-[5-(2,3-Difluorophenyl)-1-(2-methoxyethyl)-2-oxopiperidin-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide
11/18/2008US7452897 Use of substituted 2-(diaza-bicyclo-alkyl)-pyrimidone derivatives for the treatment of neurodegenerative diseases
11/18/2008US7452895 Such as N6-(4,5-dihydrooxazol-2-yl)-N4-[3-methyl-4-(6-methylpyridin-3-yloxy)-phenyl]-quinazoline-4,6-diamine; for treatment of hyperproliferative disorders such as cancer
11/18/2008US7452891 MCH antagonists and their use in the treatment of obesity
11/18/2008US7452890 Substituted pyrazoles
11/18/2008US7452888 Quinoline and aza indole compounds having pharmacological activity, for example, 8-(4-Methyl-piperazin-1-yl)-3-phenylsulfonylquinoline; use in the treatment of CNS and other disorders
11/18/2008US7452887 e.g. N-(4-(4-methylpiperazin-1-yl)phenyl)-6-phenylquinolin-4-amine;protein kinase A, C, G, tyrosine kinase, mitogen activated p38- alpha kinase inhibitor; tumor necrosis factor- alpha and interleukin-1 beta antagonist; antiinflammatory, anticarcinogenic; Alzheimer's disease, stroke, diabetes, obesity
11/18/2008US7452881 Such as N-[3-(2-diethylaminoethyl)-1H-indol-5-yl]-5-chloro-3-methylbenzo[b]thiophene-2-sulphonamide; serotonin receptors antagonist; anxiolytic, antidepressant, cognitive activator, senile dementia, psychosis, attention deficit/hyperactivity disorder
11/18/2008US7452879 Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
11/18/2008US7452878 Biaromatic compounds which activate PPARγ type receptors and cosmetic/pharmaceutical compositions comprised thereof
11/18/2008US7452874 Thrombopoietin mimetics
11/18/2008US7452873 Inhibitors of GSK-3 and uses thereof
11/18/2008US7452541 Hapten-carrier conjugates and uses thereof
11/18/2008CA2516557C Triazole compounds useful in therapy
11/18/2008CA2422379C Pyrazole compounds useful as protein kinase inhibitors
11/18/2008CA2383630C Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
11/18/2008CA2331850C Method of preparing carboxylic acid derivatives and condensing agent comprising a quaternary ammonium salt
11/18/2008CA2320822C Substituted isoindolones and their use as cyclic gmp modulators in medicaments
11/18/2008CA2305802C Amide derivatives or salts thereof
11/18/2008CA2293706C N-substituted urea inhibitors of farnesyl-protein transferase
11/18/2008CA2230516C Pyrimidine derivatives
11/13/2008WO2008137794A1 Compounds and compositions as c-kit and pdgfr kinase inhibitors
11/13/2008WO2008137770A1 Compounds and compositions as c-kit and pdgfr kinase inhibitors
11/13/2008WO2008137605A1 Pyrimidine derivatives and compositions as c-kit and pdgfr kinase inhibitors
11/13/2008WO2008136457A1 Nitrogen-containing aromatic derivative
11/13/2008WO2008136428A1 Nitrogen-containing five-membered heterocyclic compound
11/13/2008WO2008136093A1 Process for producing substituted methylamine compound and triazine derivative
11/13/2008WO2008136017A1 Aminoalkoxy aryl sulfonamide compounds and their use as 5-ht6 ligands
11/13/2008WO2008136010A1 A process for the preparation of highly pure imatinib base
11/13/2008WO2008135980A1 Imatinib production process
11/13/2008WO2008135826A2 2 -pyridine carboxamide derivatives as sodium channel modulators
11/13/2008WO2008135557A1 Organic compounds
11/13/2008WO2008135526A1 Carboxylic acid amides as factor xa inhibitors
11/13/2008WO2008135525A2 Substituted azetidines, manufacturing and use thereof as medicaments
11/13/2008WO2008135524A2 Substituted anthranilamides and analogues, manufacturing and use thereof as medicaments
11/13/2008WO2008135442A1 Heterocyclic compounds and their use as pesticides
11/13/2008WO2008134970A1 Anthranilamide compounds and the use thereof
11/13/2008WO2008134969A1 Benzamide compounds and applications thereof
11/13/2008WO2008115369A3 Inhibitors of focal adhesion kinase
11/13/2008WO2008114023A3 Phthalazinone derivatives
11/13/2008WO2008113760A3 Arylsulphonyglycine derivatives as suppressors of the interaction of glycogen phosphorylase a with the gl subunit of glycogen-associated protein phosphatase 1 (ppl) for the treatment of metabolic disorders, particulary diabetes
11/13/2008WO2008102145A3 Process for the preparation of esomeprazole magnesium dihydrate
11/13/2008WO2008099072A3 New 2, 4-dianilinopyrimidines, preparation thereof as drugs, pharmaceutical compositions and use thereof essentially as ikk inhibitors
11/13/2008WO2008097640A8 Triazole compounds that are useful in the treatment of proliferative disorders, such as cancer
11/13/2008WO2008076805B1 Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors
11/13/2008WO2008065500A3 Heteroaryl amides as type i glycine transport inhibitors
11/13/2008WO2007145563A8 Benzimidazole derivatives which are to be used as antagonist for the cb1-receptor
11/13/2008US20080281105 Novel Quinolinium Salts and Derivatives
11/13/2008US20080280967 Antiarthritic agents; antiinflammatory agents; inflammatory bowel disorders; graft verses host disease; antiulcer agents; skin disorders; respiratory system disorders; anticancer agents
11/13/2008US20080280950 Hydantoin Derivatives Useful as Metalloproteinase Inhibitors
11/13/2008US20080280949 Oxopyridyl Quinoline Amides as Nk3 Receptor Modulators
11/13/2008US20080280933 Benzimidazolyl compounds
11/13/2008US20080280925 Amines as Small Molecule Inhibitors
11/13/2008US20080280924 Pyridine and pyrimidine derivatives as mglur2 antagonists
11/13/2008US20080280920 Plasminogen Activator Inhibitor-1 Inhibitors
11/13/2008US20080280919 Quinoline and quinazoline derivatives having affinity for 5ht1-type receptors
1 ... 350 351 352 353 354 355 356 357 358 359 360 361 362 363 364 365 366 367 368 369 370 ... 1080